



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

August 31, 2022

Robert Striar
Chief Executive Officer
Bull Horn Holdings Corp.
801 S. Pointe Drive, Suite TH-1
Miami Beach, Florida 33139

Re: Bull Horn Holdings Corp.
Amendment No. 3 to Registration Statement on Form S-4
Filed August 22, 2022
File No. 333-265206

Dear Mr. Striar:

We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our August 10, 2022 letter.

Amendment No. 3 to Registration Statement on Form S-4

Closing Conditions, page 95

1. Please note that we continue to evaluate your responses to prior comments 4 and 5 and may have additional comments.

Information About Coeptis

Collaborations for Product Development - Research and Development, page 181

2. We note your disclosure that "[t]he global multiple myeloma market was \$19.48 billion in 2018 and is expected to reach \$31 billion by 2026." We direct you to prior comment 41 from our June 22, 2022 letter. Please revise to disclose the countries or jurisdictions where Vy-Gen is seeking regulatory approval for its drug product candidates and disclose

Robert Striar
Bull Horn Holdings Corp.
August 31, 2022
Page 2

the total addressable market in those countries and jurisdictions.

Statera BioPharma, page 183

3. We note your disclosure on page 183 that in August 2022, Coeptis and Statera mutually agreed to terminate their "strategic agreement." In an appropriate location, please revise your disclosure to indicate how, if at all, this development impacted the Bull Horn board of directors' view of the consideration to be paid for the Business Combination, the Vantage Point Opinion that supported the amount of the consideration to be paid for Coeptis, and the Bull Horn board of directors' conclusions that the Merger Agreement, the Business Combination and the Plans of Merger, were advisable, fair to, and in the best interests of, Bull Horn and its shareholders.

You may contact Nudrat Salik at 202-551-3692 or Tracey Houser at 202-551-3736 if you have questions regarding comments on the financial statements and related matters. Please contact Joshua Gorsky at 202-551-7836 or Tim Buchmiller at 202-551-3635 with any other questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Joshua N. Englard, Esq.